You Ma my Ma In t rel par to rel.	rocardial MR tissue tracking inuscript number (if known) the interest of transparency ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest,	failure with preserved eject study : QIMS-22-793 , we ask you to disclose all manuscript. "Related" mea e affected by the content onecessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
to me In i	the epidemiology of hyperted ication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensi he manuscript. d in this manuscript without time limit. For all other it	ive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
	meetings and, or traver				
8	Patents planned, issued or	X None			
O	pending	XNone			
	1 5				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
_					
	None.				

You Ma my Ma	rocardial MR tissue tracking nnuscript number (if known)	failure with preserved ejec study : QIMS-22-793	ction fraction in post myocardial infarction patients: a
rela par to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to i	the epidemiology of hyperto dication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	l l

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
	meetings and, or traver				
8	Patents planned, issued or	X None			
O	pending	XNone			
	1 5				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
_					
	None.				

You Ma my Ma In t rel par to rel.	rocardial MR tissue tracking inuscript number (if known) the interest of transparency ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest,	study : QIMS-22-793 , we ask you to disclose all manuscript. "Related" mea affected by the content onecessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
to me In i	the epidemiology of hyperted ication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensi he manuscript. d in this manuscript without time limit. For all other it	ve
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
	meetings and, or traver				
8	Patents planned, issued or	X None			
O	pending	XNone			
	1 5				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
_					
	None.				

You Ma my Ma In the relation relation relation relations.	cocardial MR tissue tracking inuscript number (if known) the interest of transparency ated to the content of your ties whose interests may be transparency and does not ationship/activity/interest, at following questions apply inuscript only.	failure with preserved eject study : QIMS-22-793 , we ask you to disclose all manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do to the author's relationship	os/activities/interests as they relate to the <u>current</u>	
to me In i	the epidemiology of hyperted dication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript pertai all relationships with manufacturers of antihypertensiv he manuscript. d in this manuscript without time limit. For all other ite	/e
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
	meetings and, or traver				
8	Patents planned, issued or	X None			
O	pending	XNone			
	1 5				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
_					
	None.				

You Ma my Ma In the relation relation relation relations.	cocardial MR tissue tracking inuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, at following questions apply inuscript only.	failure with preserved eject study : QIMS-22-793 , we ask you to disclose all manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do to the author's relationship	os/activities/interests as they relate to the <u>current</u>	
to me In i	the epidemiology of hyperted ication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript pertai all relationships with manufacturers of antihypertensiv he manuscript. d in this manuscript without time limit. For all other ite	/e
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
	meetings and, or traver				
8	Patents planned, issued or	X None			
O	pending	XNone			
	1 5				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
_					
	None.				

Da	te:Nov. 20 th , 2022	_			
Your Name:Zhaoxin Tian					
Ma	Manuscript Title: Heart failure with preserved ejection fraction in post myocardial infarction patients: a				
my	ocardial MR tissue tracking	study			
Ma	anuscript number (if known)	: QIMS-22-793			
In rel pa to rel Th ma	the interest of transparency ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/activite epidemiology of hypertedication, even if that medicated the epidemiology of the epidemiology of that medicated in the epidemiology of the epidemiology of that medicated in the epidemiology of the epidemiolo	we ask you to disclose all manuscript. "Related" mease affected by the content of necessarily indicate a bias. it is preferable that you do to the author's relationship wities/interests should be ension, you should declare ation is not mentioned in the poort for the work reported.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initial	planning of the work		
1	All support for the present	XNone			
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article processing charges, etc.)				
	No time limit for this item.				
		Time frame: past	26 months		
2	Grants or contracts from	X None	30 months		
_	any entity (if not indicated	A_NONE			
	in item #1 above).				
3	Royalties or licenses	XNone			
	Consulting fees	Y None			
1					

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
	meetings and, or traver				
8	Patents planned, issued or	X None			
O	pending	XNone			
	1 5				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
_					
	None.				

Ma my Ma In t rela par	rocardial MR tissue tracking inuscript number (if known) the interest of transparency ated to the content of your tries whose interests may be	failure with preserved eject study : QIMS-22-793 , we ask you to disclose all manuscript. "Related" mea	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
The	ationship/activity/interest, e following questions apply inuscript only.		ps/activities/interests as they relate to the <u>current</u>
to me	the epidemiology of hypertedication, even if that medic	ension, you should declare ation is not mentioned in t oport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	X None	<u> </u>

5	Payment or honoraria for	XNone			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Consent for attending	V Nego			
′	Support for attending meetings and/or travel	XNone			
	meetings and/or traver				
8	Patents planned, issued or	X None			
0	pending	XNOTIE			
	periamg				
0	Dankisia ski sa sa sa Data	V Name			
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
DI.	Discourse the short and interest in the fall and a bound				
716	Please summarize the above conflict of interest in the following box:				
None.					
	Hone.				

Da	ite:Nov. 20 th , 2022			
Yo	ur Name:Shiqi Jin			
Ma	anuscript Title: Heart	failure with preserved eje	ection fraction in post myocardial infarction patients: a	
-	ocardial MR tissue tracking			
Ma	anuscript number (if known)	: QIMS-22-793		
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. hips/activities/interests as they relate to the current	
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	e defined broadly. For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other ite	е
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
_	l			
1	All support for the present manuscript (e.g., funding, provision of study materials,	X_None		
	medical writing, article processing charges, etc.) No time limit for this item.			
	processing charges, etc.)	Time frame: pas	t 36 months	
2	processing charges, etc.) No time limit for this item. Grants or contracts from	Time frame: pasXNone	t 36 months	
2	processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated		t 36 months	
	processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months	
2	processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated		t 36 months	
	processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months	

5	Payment or honoraria for	XNone			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Consent for attending	V Nego			
′	Support for attending meetings and/or travel	XNone			
	meetings and/or traver				
8	Patents planned, issued or	X None			
0	pending	XNOTIE			
	periamg				
0	Dankisia ski sa sa sa Data	V Name			
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
DI.	Discourse the short and interest in the fall and a bound				
716	Please summarize the above conflict of interest in the following box:				
None.					
	Hone.				

Da	te:Nov. 20 th , 2022				
	ur Name: Huaibi Huo				
		failure with preserved ejec	ction fraction in post myocardial infarction patients: a		
myocardial MR tissue tracking study					
Manuscript number (if known): QIMS-22-793					
rel to rel The ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply inuscript only.	manuscript. "Related" mede affected by the content of the author's relationship ivities/interests should be	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains		
		· •	all relationships with manufacturers of antihypertensive		
me	edication, even if that medic	ation is not mentioned in t	the manuscript.		
	item #1 below, report all su e time frame for disclosure i	• •	d in this manuscript without time limit. For all other items,		
		Name all entities with	Specifications/Comments		
		whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your		
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)		
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)		
1	All support for the present	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone	(e.g., if payments were made to you or to your institution) I planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone Time frame: past	(e.g., if payments were made to you or to your institution) I planning of the work		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone Time frame: past	(e.g., if payments were made to you or to your institution) I planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone Time frame: past	(e.g., if payments were made to you or to your institution) I planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone Time frame: past	(e.g., if payments were made to you or to your institution) I planning of the work		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone Time frame: pastXNone	(e.g., if payments were made to you or to your institution) I planning of the work		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia XNone Time frame: pastXNone	(e.g., if payments were made to you or to your institution) I planning of the work		

5	Payment or honoraria for	XNone			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Consent for attending	V Nego			
′	Support for attending meetings and/or travel	XNone			
	meetings and/or traver				
8	Patents planned, issued or	X None			
0	pending	XNOTIE			
	periamg				
0	Dankisia ski sa sa sa Data	V Name			
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
DI.	Discourse the short and interest in the fall and a bound				
716	Please summarize the above conflict of interest in the following box:				
None.					
	Hone.				

You Ma my Ma	rocardial MR tissue tracking nnuscript number (if known)	failure with preserved ejec study : QIMS-22-793	ction fraction in post myocardial infarction patients: a
rel par to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply inuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to me	the epidemiology of hyperted ication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	Y None	

5	Payment or honoraria for	XNone			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Consent for attending	V Nego			
′	Support for attending meetings and/or travel	XNone			
	meetings and/or traver				
8	Patents planned, issued or	X None			
0	pending	XNOTIE			
	periamg				
0	Dankisia ski sa sa sa Data	V Name			
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
DI.	Discourse the short and interest in the fall and a bound				
716	Please summarize the above conflict of interest in the following box:				
None.					
	Hone.				